NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.330
+0.020 (1.53%)
Aug 21, 2026, 4:00 PM EDT - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,155,856
Market Cap
30.30M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 0 | - |
| Jun 30, 2023 | 7 | -10 | -58.82% |
| Jun 30, 2022 | 17 | 0 | - |
| Jun 30, 2021 | 17 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| BeyondSpring | 44 |
| NextCure | 40 |
| Enlivex | 34 |
| Kyntra Bio | 34 |
| BriaCell Therapeutics | 16 |
| Lantern Pharma | 16 |
| Genenta Science | 9 |
NNVC News
- 1 day ago - NanoViricides registers to sell 2.52M shares of common stock for holders - TheFly
- 4 days ago - NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’ - TheFly
- 4 days ago - The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon - Accesswire
- 12 days ago - NanoViricides receives regulatory approval for Phase II trial of NV-387 - TheFly
- 12 days ago - NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak - Accesswire
- 25 days ago - NanoViricides awaits regulatory approval to being Phase II trial of NV-387 - TheFly
- 25 days ago - NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial - Accesswire
- 4 weeks ago - NanoViricides prices $3.8M registered direct offering - TheFly